Prof. Roberto Motterlini
INSERM, Equipe 3
Faculty of Medicine
8 Rue du Général Sarrail
Dr. Motterlini is focussing his research on the biological significance of the heme oxygenase/carbon monoxide (CO) pathway in mammals. In recent years Dr. Motterlini pioneered the identification and characterization of CO-releasing molecules (CO-RMs), a new class of compounds that carry and deliver precise amounts of CO gas to tissues and exert a variety of important pharmacological activities. His main objectives within the COST Action are : 1) to develop biologically compatible CO-RMs that can be utilized therapeutically to treat vascular- and inflammatory-releated disorders ; 2) to identify the intracellular target(s) of CO that mediates its beneficial effects.
Selected Recent Publications
- Desmard M, Foresti R, Morin D, Denamur E, Crook S, Mann BE, Scapens D, Montravers P, Boczkowski J and Motterlini R. Differential antibacterial activity against Pseudomonas aeruginosa by carbon monoxide-releasing molecules (CO-RMs) Antiox. Redox Signal. (In press), 2011.
- Yabluchanskiy A, Sawle P, Homer-Vanniasinkam S, Green CJ, Foresti R and Motterlini R. CORM-3, a carbon monoxide-releasing molecule, alters the inflammatory response and reduces brain damage in a rat model of hemorrhagic stroke. Crit. Care Med. (In press), 2011.
- Motterlini R and Otterbein LE. The therapeutic potential of carbon monoxide. Nat. Rev. Drug Discov. 9:728-743, 2010.